ADVERTISEMENT

BioMarker Strategies Announces that Both of Its Core Diagnostics Technologies for Solid Tumor Cancers Are Now Covered by Patents Granted in Korea

ROCKVILLE, Md.--(BUSINESS WIRE)--Jun 3, 2019--

BioMarker Strategies LLC today announced that the Korean Patent Office has granted a new patent covering its PathMAP® Functional Signaling Profile technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190603005237/en/

The SnapPath® Cancer Diagnostics System is the only diagnostics system that can generate purified populations of live solid tumor cells from live, unfixed samples in an automated and standardized manner. SnapPath preserves the molecular integrity of these living cells for ex vivo exposure to targeted therapies and combinations, including combinations with immunotherapies. This enables generation of PathMap® Functional Signaling Profiles, which are highly predictive of individual solid tumor response to targeted therapies, because they are based on the dynamic, predictive signaling information available only from live cells. Demonstrations of the SnapPath® Cancer Diagnostics System will be provided this week during Exhibit hours at the BIO 2019 International Convention in Philadelphia. (Photo: Business Wire)

“PathMAP Functional Signaling Profiles are highly predictive of individual solid tumor responses to targeted therapies and combinations because they are based on the dynamic, predictive signaling information available only from live cells,” said Jerry Parrott, President and CEO, BioMarker Strategies.

PathMAP Functional Signaling Profiles are made possible by the Company’s proprietary SnapPath® Cancer Diagnostics System, which was developed specifically to enable predictive tests to guide targeted drug development and treatment selection for patients with solid tumor cancers. SnapPath is the only diagnostics system that can generate purified populations of live solid tumor cells from live, unfixed samples in an automated and standardized manner. The system preserves the molecular integrity of these living cells for ex vivo exposure to targeted therapies on the SnapPath System. The Korean Patent Office previously granted a patent covering the Company’s SnapPath® Cancer Diagnostics System technology in 2018.

“Patents on both of our core technologies have now been granted in the United States, Europe, Australia, Canada, Japan and Korea,” said Mr. Parrott. “These and other granted patents give us broad protection to advance our mission to enable the use of live cells to personalize drug development and treatment selection for patients with solid tumor cancers.”

Patents Granted BioMarker Strategies for Its SnapPath® Cancer Diagnostics System: “Improved Methods and Devices for Cellular Analysis”

                 

Country/Region

Patent #

Issue Date

Expiration

United States US9121801 September 1, 2015 December 28, 2030
Europe EP2210080 January 28, 2015 October 24, 2028
Australia AU2008317329 January 15, 2015 October 24, 2028
Australia AU2014277688 January 19, 2017 October 24, 2028

Canada

CA2703631

August 22, 2017

October 24, 2028

Hong Kong HK1145878

August 14, 2015

October 24, 2028

Japan JP6177841 July 21, 2017 October 24, 2028
Korea KR10-1658245 September 9, 2016 October 24, 2028
 

Patents Granted for the Company’s PathMAP® Functional Signaling Profile Technology: “Compositions for Prediction of Drug Sensitivity, Resistance and Disease Progression”*

                 

Country/Region

Patent #

Issue Date

Expiration

United States US9766249 September 19, 2017 August 31, 2025
Europe EP2561368 August 2, 2017 April 18, 2031
Australia AU2011242990 May 28, 2015 April 18, 2031
Canada CA2795362 March 20, 2018 April 18, 2031

China

ZL201180030332.9

April 13, 2018 April 18, 2031
Japan JP6158078 June 16, 2017 April 18, 2031
Korea KR10-1977875 May 7, 2019 April 18, 2031
Singapore SG184507 May 6, 2015 April 18, 2031
 

The SnapPath and PathMAP technologies are ideally suited to assess response to targeted drugs and combinations, including combinations with Immunotherapies, in development for the treatment of solid tumor cancers.

About BioMarker Strategies

BioMarker Strategies is a privately-held molecular diagnostics company founded in 2006 at The Johns Hopkins Science & Technology Park in Baltimore, and now based in Rockville, Maryland. The Company’s mission is to help make personalized medicine more of a reality for patients with solid tumor cancers, by providing powerful new molecular tools and research services to guide targeted drug development and treatment selection for these patients. For more information about BioMarker Strategies, please see www.biomarkerstrategies.com.

Forward-Looking Statements

The information in this press release includes our projections and other forward-looking statements regarding future events. In some cases, forward-looking statements may be identified by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “projects,” “estimates,” “predicts,” “potential,” “continue”, etc. These statements are not guarantees of future performance or achievement and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is projected here.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190603005237/en/

CONTACT: Jerry Parrott, President & CEO

301-938-4043 Mobile

[email protected]

KEYWORD: UNITED STATES ASIA PACIFIC NORTH AMERICA MARYLAND SOUTH KOREA

INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES ONCOLOGY

SOURCE: BioMarker Strategies LLC

Copyright Business Wire 2019.

PUB: 06/03/2019 08:00 AM/DISC: 06/03/2019 08:01 AM

http://www.businesswire.com/news/home/20190603005237/en

Bg pattern light

UPGRADE TO PREMIUM

Subscribe to Samoa Observer Online

Enjoy access to over a thousand articles per month, on any device as well as feature-length investigative articles.

Ready to signup?